US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

13.22

+0.13000.99%

Post-market: 13.220.00000.00%17:48 EST

Volume:273.03K

Turnover:3.60M

Market Cap:730.47M

PE:9.40

High:13.24

Open:13.11

Low:13.11

Close:13.09

52wk High:13.59

52wk Low:11.87

Shares:55.25M

Float Shares:55.25M

Volume Ratio:1.06

T/O Rate:0.49%

Dividend:1.53

Dividend Rate:11.60%

EPS(TTM):1.41

ROE:--

ROA:--

PB:0.92

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

CPF vs REITs: Which Builds a Stronger Retirement Income Stream in 2026?

The Smart Investor

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Press Release: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RA"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":13.22,"timestamp":1770411600000,"preClose":13.09,"halted":0,"volume":273027,"hourTrading":{"tag":"盘后","latestPrice":13.22,"preClose":13.22,"latestTime":"17:48 EST","volume":16,"amount":211.46,"timestamp":1770418094895,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.009931245225362931,"floatShares":55245934,"shares":55254696,"eps":1.406,"marketStatus":"Market Closed","change":0.13,"latestTime":"02-06 16:00:00 EST","open":13.11,"high":13.24,"low":13.11,"amount":3601486.844,"amplitude":0.009931,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.406,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":13.09,"dividendRate":0.116044,"preHourTrading":{"tag":"盘前","latestPrice":13.09,"preClose":13.09,"latestTime":"08:00 EST","volume":6,"amount":78.548496,"timestamp":1770382808912,"change":0,"changeRate":0,"amplitude":0.00013},"postHourTrading":{"tag":"盘后","latestPrice":13.22,"preClose":13.22,"latestTime":"17:48 EST","volume":16,"amount":211.46,"timestamp":1770418094895,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0643813700758773},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55245934,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0643813700758773,"shares":55254696,"dividePrice":1.5341,"high":13.24,"amplitude":0.009931,"preClose":13.09,"low":13.11,"week52Low":11.87,"pbRate":"0.92","week52High":13.59,"institutionHeld":0,"latestPrice":13.22,"eps":1.406,"divideRate":0.116044,"volume":273027,"delay":0,"ttmEps":1.406,"open":13.11,"prevYearClose":12.96,"prevWeekClose":13.02,"prevMonthClose":13.02,"prevQuarterClose":12.96,"fiveDayClose":13.02,"twentyDayClose":12.83,"sixtyDayClose":13.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2026-03-12","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-12","defaultRemindTime":1773322200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-26","payableDate":"2026-03-12","currency":"USD","dateTimestamp":1773288000000,"payDate":"2026-03-26"},{"date":"2026-02-05","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-05","defaultRemindTime":1770301800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-19","payableDate":"2026-02-05","currency":"USD","dateTimestamp":1770267600000,"payDate":"2026-02-19"},{"date":"2026-01-08","symbol":"RA","amount":0.118,"announcedDate":"2025-12-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-08","defaultRemindTime":1767882600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-22","payableDate":"2026-01-08","currency":"USD","dateTimestamp":1767848400000,"payDate":"2026-01-22"},{"date":"2025-12-11","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-11","defaultRemindTime":1765463400000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-11","currency":"USD","dateTimestamp":1765429200000,"payDate":"2025-12-26"},{"date":"2025-11-13","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-13","defaultRemindTime":1763044200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-28","payableDate":"2025-11-13","currency":"USD","dateTimestamp":1763010000000,"payDate":"2025-11-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603262769","title":"CPF vs REITs: Which Builds a Stronger Retirement Income Stream in 2026?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603262769","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603262769?lang=en_us&edition=fundamental","pubTime":"2026-01-15 11:30","pubTimestamp":1768447800,"startTime":"0","endTime":"0","summary":"CPF offers certainty and safety, while REITs provide higher income potential. As retirement planning evolves in 2026, we compare how each stacks up as a long-term income stream.","market":"nz","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2026/01/CPF-Vs-REITs-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2026/01/CPF-Vs-REITs-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/cpf-vs-reits-which-builds-a-stronger-retirement-income-stream-in-2026/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/cpf-vs-reits-which-builds-a-stronger-retirement-income-stream-in-2026/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["BK4017","BK6082","AJBU.SI","BK6011","BK6131","CPF","BK6133","BUOU.SI","BK6014","BK6137","BK6512","CFA.SI","CFA","C38U.SI","RA","BK6072","BK4211"],"gpt_icon":0},{"id":"2603686974","title":"Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686974","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686974?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:00","pubTimestamp":1768305600,"startTime":"0","endTime":"0","summary":"KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027  KT-579 Phase 1 HV clinical trial expect","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217633/0/en/Kymera-Therapeutics-Outlines-Key-2026-Objectives-and-Strategy-to-Advance-Industry-Leading-Portfolio-of-Oral-Immunology-Programs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BP","BK4096","AD","LU1829250122.USD","BK4139","EASI","LU0162691827.USD","LU0320765646.SGD","IBD","PN","RA","LU1162221912.USD","BK4201","BK4585","LU0072461881.USD","BK4132","BK4588"],"gpt_icon":0},{"id":"2602510876","title":"Press Release: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510876","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510876?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"\"6 in '26\" expected proof-of-concept  readouts across SKYLINE and SKYWAY trials. SKYLINE platform trial in ulcerative colitis  recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in Q2. SKYWAY basket trial enrollment on track across rheumatoid arthritis , psoriatic arthritis , and axial spondyloarthritis ; All readouts expected in 4Q 2026. WALTHAM, Mass., Jan. 12, 2026  -- Spyre Therapeutics, Inc. , a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease  and rheumatic diseases, today highlighted its 2026 priorities including six expected POC readouts . The Company also expanded its leadership team with the appointment of Kate Tansey Chevlen as CCO. Ms. Tansey Chevlen is a seasoned biopharma commercial leader with nearly two decades of experience driving strategy, execution, and growth across U.S. an","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2294711713.HKD","SYRE","BK4539","CCO","LU0823414478.USD","LU0823414551.USD","BK4007","BK4139","LU2357125470.USD","LU2249611893.SGD","RA","LU2506951792.HKD","BK4009","LENZ"],"gpt_icon":0},{"id":"2602565191","title":"Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2602565191","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602565191?lang=en_us&edition=fundamental","pubTime":"2026-01-12 08:00","pubTimestamp":1768176000,"startTime":"0","endTime":"0","summary":"HANGZHOU, China, SHANGHAI and BOSTON, Jan. 12, 2026 /PRNewswire/ --Lynk Pharmaceuticals Co., Ltd. , a clinical stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today announced positive topline results from its Phase III clinical trial evaluating zemprocitinib  in patients with moderate to severe active rheumatoid arthritis . The study met its primary and key secondary efficacy endpoints, demonstrating statistically significant improvements versus placebo , with a favorable safety and tolerability profile.Professor Xiaofeng Zeng, the principal investigator of this study from Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, said: \"Rheumatoid arthritis is a chronic, progressive autoimmune disease that can severely impact patients' quality of life and physical health. In this Phase III study, zemprocitinib demonstrated strong ef","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/lynk-pharmaceuticals-announces-positive-phase-iii-topline-data-of-zemprocitinib-lnk01001-in-rheumatoid-arthritis-302657982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZK","BK4134","III","RA","BK4099"],"gpt_icon":0}],"pageSize":4,"totalPage":9,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RA\",params:#limit:6,delay:false,,,undefined,":[]}}